Thermo Fisher Scientific Oral Solid Dose Facility Expands Capabilities
Bourgoin hub broadens customer needs to also address commercial manufacturing.
Thermo Fisher Scientific, a contract development and manufacturing organization (CDMO), is adding early development work for oral solid dose therapies to its Bourgoin, France site, allowing that location to address customers’ workflow, starting with early drug development through commercial manufacturing.
Back in 2021, the French government’s France Relance economic stimulus plan provided a grant to support the early development hub. Construction work began during Q1 2022, leading to first activities being launched in June 2022.
“In the last decade, Thermo Fisher has led and advanced the field of oral solid dose development, with 126 new drug approvals supported,” says Leon Wyszkowski, Thermo Fisher’s president of pharma services commercial operations. “Expanding our capabilities in France is a further investment in our global oral solid network that will allow us to further forge partnerships with customers who depend on our capabilities for the development and commercial production of lifesaving drugs for their patients.”
Touchlight, University of Nottingham Collaborate on Development of Zika Vaccine
August 21st 2024Although it still has to undergo the preclinical and clinical trial process, the DNA vaccine—which could be created in as little as six weeks—does not require the cold chain storage that mRNA jabs often demand.
